Business
As Israeli pharmaceutical giant Teva pushes ahead with a $40-billion dollar hostile bid for US generic drugmaker Mylan, Brent Saunders, CEO of...
Hi, what are you looking for?
Jewish Business News
Business
Deal to give Perrigo manufacturing technology for softgel products
Business
Bloomberg reports Mylan chairman Robert Coury as telling investors he is prepared to reduce Perrigo shareholders' risk
Business
Teva declined the chance because it does not operate in the store-brand OTC market, Perrigo's main activity.
Business
Reuters Exclusive: Generics drugmaker Mylan NV (MYL.O), which is in the middle of a three-way takeover battle, has said it is unwilling to...
Business
When Mylan and Perrigo executives had a “very preliminary” discussion a year ago about possibly merging the two generic drug companies, Perrigo was a...
Business
Nonalcoholic Steatohepatitis is a progressive liver disease associated with increased risk for liver cirrhosis, hepatocellular cancer, metabolic and cardiovascular disease .
Business
John Paulson's hedge fund has increased its holdings in Mylan NV to 4.5%.
Business
Mylan's filing on executive compensation reveals much higher pay than at Teva.
Business
[FULL LETTER] After Mylan Responded aggressively to Teva's bid, Erez Vigodman says in an open letter to Robert Coury: Shareholders won't benefit from Mud...